Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

BACKGROUND: The dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the treatment of B cell malignancies, their clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Reinoso, Anaïs, Tirado, Néstor, Martinez-Moreno, Alba, Díaz, Víctor M, García-Peydró, Marina, Hangiu, Oana, Díez-Alonso, Laura, Albitre, Ángela, Penela, Petronila, Toribio, Maria L, Menéndez, Pablo, Álvarez-Vallina, Luis, Sánchez Martínez, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791403/
https://www.ncbi.nlm.nih.gov/pubmed/36564128
http://dx.doi.org/10.1136/jitc-2022-005333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791403/
https://www.ncbi.nlm.nih.gov/pubmed/36564128
http://dx.doi.org/10.1136/jitc-2022-005333

Ejemplares similares